Начало・Списък с акции・MediciNova Inc

MediciNova Inc

Затворен

СекторЗдравеопазване

1.31 1.55

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.28

Максимум

1.31

Ключови измерители
By Trading Economics
Приходи	216K -2.6M
Продажби	35K 187K
EPS	-0.05
Марж на печалбата	-1,383.144
Служители	6
EBITDA	312K -2.5M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+501.5% upside

Дивиденти
By Acuity
Следващи печалби	12.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-4.4M 65M
Предишно отваряне	-0.24
Предишно затваряне	1.31

Настроения в новините

By Acuity

43%

57%

135 / 340 Класиране в Healthcare

MediciNova Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

3.08.2026 г., 20:06 ч. UTC

MediciNova Inc. shares are lower, continuing a decline since Friday's close, despite positive movements in major indices like the S&P 500 and Nasdaq 100.

31.07.2026 г., 19:56 ч. UTC

Shares of MediciNova Inc. are lower during Friday's session, following a routine decline after an early high. The stock is below its 20-day moving average.

30.07.2026 г., 20:51 ч. UTC

MediciNova Inc's shares are lower in after-market hours, reflecting a broader decline in the Biotechnology sub-sector. The asset is near its one-month trading range low.

29.07.2026 г., 20:09 ч. UTC

MediciNova Inc shares are lower today, continuing a decline since Tuesday's close, and remain near their opening low amid broader market trends.

28.07.2026 г., 18:46 ч. UTC

MediciNova Inc. shares are trading higher today, remaining above Monday's close despite settling back from earlier gains during the session.

27.07.2026 г., 19:06 ч. UTC

MediciNova Inc. shares are lower today, reflecting broader market trends amid a significant decline in crude oil prices following eased geopolitical tensions.

24.07.2026 г., 23:02 ч. UTC

MediciNova Inc shares increased in after-hours trading, reflecting strong performance since Friday's close, despite mixed market sentiment and no specific company news.

23.07.2026 г., 20:06 ч. UTC

MediciNova Inc. shares are lower today, continuing a six-session decline amid routine volatility and remaining significantly below the 20-day moving average.

21.07.2026 г., 19:21 ч. UTC

MediciNova Inc. shares are lower amid no specific news, continuing a trend below the 20-day moving average over the past three sessions.

Сравнение с други в отрасъла

Ценова промяна

MediciNova Inc Прогноза

Ценова цел

By TipRanks

501.5% нагоре

12-месечна прогноза

Среден 8 USD 501.5%

Висок 10 USD

Нисък 6 USD

Според 2 анализатори от Wall Street, предложили 12-месечна ценова цел за MediciNova Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

2 ratings

Купи

Задържане

Продай

Според 2 анализатори, дали борсови рейтинги на MediciNova Inc през последните 3 месеца.

Настроение

By Acuity

135 / 340 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно MediciNova Inc

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.